Cellectis S.A.CLLS

NasdaqHealthcareBiological Products, (No Diagnostic Substances)
Price (close)
$1.47
Market cap
—
P/E
—
Revenue (FY)
$72.9M
Net income
-$67.6M
Dividend yield
—
1-year total return
-55.7%
Net margin
-92.7%
Revenue growth
75.8%
Debt / equity
—

What Cellectis S.A. does.

No business description on file yet.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$51.1M$30.3M$19.2M$755,000$41.5M$72.9M
Net income-$81.1M-$114.2M-$106.1M-$101.1M-$36.8M-$67.6M
Free cash flow-$124.3M-$123.1M-$89.9M-$25.8M$20.4M-$41.8M

More on CLLS.

Figures from Cellectis S.A.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.